New vaccination technology for endogenous antigen-derived ailments

IDrugs

Volumn 11, Issue 2, 2008, Pages 111-115

  Barabas, A Z ^a   Cole, C D ^b   Barabas, A D ^a   Bahlis, N J ^c   Lafreniere, R ^a  

^a Health Sciences Centre Calgary   (Canada)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Autoantibody (aAb); Autoantigen (aAg); Autoimmunity; Cancer; Immune complex (IC); Modified vaccination technique (MVT)

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; HYDRALAZINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; ISONIAZID; NEPHRITOGENIC ANTIGEN; PROCAINAMIDE; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL KILLING; CELL SURFACE; CYTOLYSIS; DISEASE COURSE; HEYMANN NEPHRITIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOTHERAPY; INFECTION; MOLECULAR MIMICRY; NEOPLASM; NONHUMAN; REVIEW; T LYMPHOCYTE; TEMPERATURE; VACCINATION;

ANIMALS; AUTOIMMUNE DISEASES; BIOTECHNOLOGY; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MODELS, IMMUNOLOGICAL; TREATMENT OUTCOME; VACCINATION;

EID: 38849085744     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (0)